HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

DOTA(0)-Tyr(3)-Thr(8)- 111In-octreotate

can be used in peptide receptor-mediated radionuclide therapy

Also Known As:

111In-octreotate, DOTA(0)-Tyr(3)-Thr(8)-; 111In-0-DOTA-3-Tyr-8-Thr-octreotide; 111In-DOTATATE; 111In-octreotate, DOTA(0)-tyrosyl(3)-threonyl(8)-

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Organometallic Compounds: 64
  - DOTA(0)-Tyr(3)-Thr(8)- 111In-octreotate: 2
Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - Octreotide: 5228
      - DOTA(0)-Tyr(3)-Thr(8)- 111In-octreotate: 2
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - Octreotide: 5228
      - DOTA(0)-Tyr(3)-Thr(8)- 111In-octreotate: 2

Experts

1.	Atcher, Robert W: 1 article (12/2016)
2.	Breeman, Wouter A: 1 article (12/2016)
3.	Chan, Ho Sze: 1 article (12/2016)
4.	Daniels, Tamara: 1 article (12/2016)
5.	Konijnenberg, Mark W: 1 article (12/2016)
6.	Makvandi, Mehran: 1 article (12/2016)
7.	Norenberg, Jeffrey P: 1 article (12/2016)
8.	Nysus, Monique: 1 article (12/2016)
9.	de Blois, Erik: 1 article (12/2016)
10.	de Jong, Marion: 1 article (12/2016)

Related Diseases

1.

Neoplasms (Cancer)

02/01/2023 - "Biokinetic data of 111In-DOTATATE in tumors, kidneys, liver, spleen, and whole body were obtained from eight patients using planar scintigraphic imaging at T1 = (2.9 ± 0.6), T2 = (4.6 ± 0.4), T3 = (22.8 ± 1.6), T4 = (46.7 ± 1.7) and T5 = (70.9 ± 1.0) h post injection. "
12/01/2016 - "Tumor uptake was similar for 111In-DOTATATE and 213Bi-DOTATATE at 0.3 nmol peptide. "
12/01/2016 - "Tumor uptake and kinetics as a function of injected mass of peptide (range 0.03-3 nmol) were investigated using 111In-DOTATATE. "

Related Drugs and Biologics

1.	Peptides (Polypeptides)